XVII.g

Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)

This includes classic presentations of pulmonary TB and miliary tuberculosis which can be severe or fatal. A search for extrapulmonary TB is indicated in all cases. Drug-associated TB can occur via reactivation of prior latent TB or it is newly acquired. TB can be pulmonary, thoracic, extrathoracic or disseminated. See also under XVIIf, XVIIh, XVIIi

Last update : 21/01/2015
 

Causative drugs

27

Abused drugs/substances (illicit-, street drugs - IV/inhaled)

I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.g IV - Airway involvement
IV.g - Syncope - Cough syncope
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.q V - Pleural and/or pericardial involvement
V.q - Empyema
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VI.j VI - Pulmonary vasculopathy
VI.j - Mercury pulmonary embolism
VI.r VI - Pulmonary vasculopathy
VI.r - Septic pulmonary embolism
VI.t VI - Pulmonary vasculopathy
VI.t - Pulmonary artery aneurysm(s)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.d VIII - Upper, central, large airway involvement
VIII.d - Thermal (burns, frostbite), chemical, or caustic facial and/or airway injury
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism - Wound botulism
X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic reactions, syndromes and conditions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.i XII - Cardiovascular involvement / toxicity
XII.i - Endocarditis (infective)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.ag XV - Pulmonary pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy
XV.al XV - Pulmonary pathology
XV.al - Path: Pulmonary hypertension incl. angiomatoid vasculopathy
XVI.v XVI - Imaging
XVI.v - Imaging: Diffuse centrilobular micronodules
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to progressive massive fibrosis (PMF)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
XVII.s XVII - Infections & related conditions
XVII.s - Sternoclavicular septic arthritis
XVII.u XVII - Infections & related conditions
XVII.u - Epidural abscess
2

Adalimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
X.b X - Systemic reactions, syndromes and conditions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.s X - Systemic reactions, syndromes and conditions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.aa XVII - Infections & related conditions
XVII.aa - Coccidioidomycosis
1

Chemotherapy, antineoplastic

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Acute/subacute pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.n X - Systemic reactions, syndromes and conditions
X.n - Tumor lysis syndrome (TLS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.l XV - Pulmonary pathology
XV.l - Path: Pulmonary fibrosis, unclassifiable
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.am XV - Pulmonary pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
1

Corticosteroids, systemic (oral, parenteral)

I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VI.ad VI - Pulmonary vasculopathy
VI.ad - Right ventricular outflow tract compression
VII.c VII - Mediastinal involvement
VII.c - Mediastinal lipomatosis
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs
VIII.g VIII - Upper, central, large airway involvement
VIII.g - Tracheal narrowing - Sabre sheath trachea
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.m IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.m - Epidural thoracic lipomatosis
IX.v IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.v - Myopathy/muscle weakness or paralysis
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.n X - Systemic reactions, syndromes and conditions
X.n - Tumor lysis syndrome (TLS)
X.as X - Systemic reactions, syndromes and conditions
X.as - Scleroderma renal crisis
X.av X - Systemic reactions, syndromes and conditions
X.av - Hypogammaglobulinemia-Antibody deficiency (see under XVIIw)
XI.v XI - Miscellaneous
XI.v - Rib fracture
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.ai XI - Miscellaneous
XI.ai - Cushing syndrome
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XVI.at XVI - Imaging
XVI.at - Imaging: Subpleural fat deposits
XVI.au XVI - Imaging
XVI.au - Imaging: Mediastinal fatty deposits
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary infection
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.v XVII - Infections & related conditions
XVII.v - Strongyloides stercoralis hyperinfection (w/wo DAH)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
XVII.ai XVII - Infections & related conditions
XVII.ai - A falsely negative/indeterminate IGRA test result
3

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.m X - Systemic reactions, syndromes and conditions
X.m - Pulmonary/systemic vasculopathy/vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic reactions, syndromes and conditions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ar X - Systemic reactions, syndromes and conditions
X.ar - Relapse/flare/onset of Crohn's disease
XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
3

Imatinib

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Acute/subacute pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.n X - Systemic reactions, syndromes and conditions
X.n - Tumor lysis syndrome (TLS)
X.r X - Systemic reactions, syndromes and conditions
X.r - Fluid retention
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic)
XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.n XV - Pulmonary pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary infection
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Immune checkpoint inhibitors (ICPI) - ICPI combinatorial therapy

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.am X - Systemic reactions, syndromes and conditions
X.am - Immune-related adverse effect/toxicity
X.aw X - Systemic reactions, syndromes and conditions
X.aw - Connective tissue disease
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Infliximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.b X - Systemic reactions, syndromes and conditions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.h X - Systemic reactions, syndromes and conditions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.s X - Systemic reactions, syndromes and conditions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ah X - Systemic reactions, syndromes and conditions
X.ah - Granulomatosis with polyangiitis (w/wo ANCA) or flare of
X.ar X - Systemic reactions, syndromes and conditions
X.ar - Relapse/flare/onset of Crohn's disease
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ac XVII - Infections & related conditions
XVII.ac - Actinomycosis
5

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.b X - Systemic reactions, syndromes and conditions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
1

Leflunomide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
3

Marijuana, cannabis (haschish, hash, bang, dab)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
X.ac X - Systemic reactions, syndromes and conditions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.s XI - Miscellaneous
XI.s - Death following inhalation of compound - Sniffing death
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
1

Nivolumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.y IV - Airway involvement
IV.y - Eosinophilic airways disease/bronchiolitis
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause ARF)
IX.y IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.y - A flare or relapse of preexisting myasthenia gravis
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
5

TNF-alpha antagonists/inhibitors

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic reactions, syndromes and conditions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis
X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.m X - Systemic reactions, syndromes and conditions
X.m - Pulmonary/systemic vasculopathy/vasculitis (ANCA status MPO, unknown or negative)
X.p X - Systemic reactions, syndromes and conditions
X.p - Serum sickness-like reaction
X.s X - Systemic reactions, syndromes and conditions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.x X - Systemic reactions, syndromes and conditions
X.x - Subclinical ANCA positivity
X.ae X - Systemic reactions, syndromes and conditions
X.ae - Antisynthetase antibodies (ASA)-ASA syndrome
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
5